Long-term side-effects of targeted therapies in pediatric cancer patients
A University of Colorado Cancer Center review published this week in the journal Lancet Oncology describes possible long-term side-effects of new, targeted therapies in pediatric cancer patients: what we don't know may hurt us.
"As pediatricians who treat kids with cancer, we expect the side-effects of traditional chemotherapies: low white blood count, infections, even long-term heart trouble or infertility. But there's the impression that these new, molecularly targeted agents are much less toxic. That may be true, especially in adult patients, but until we have more information about the long-term effects of these therapies in children, we need to be careful about how and when we prescribe them," says Chris Porter, MD, CU Cancer Center investigator and assistant professor of Pediatrics at the University of Colorado School of Medicine.
Already we know that molecularly targeted therapies may stunt the growth of pediatric patients, delay puberty or speed the onset of diabetes. And researchers are just now starting to ask about additional, sometimes unforeseen side-effects, potentially including more subtle issues such as neurocognitive, balance and motor defects.
"The growth of cancer cells isn't that different than the growth of a 7-pound baby into a 210-pound teenage linebacker. Now, you shut down these growth pathways in an adult and it might not be a big deal, but you shut down these same pathways at a critical time in childhood development and you can have real problems," says Lia Gore, MD, CU Cancer Center investigator and associate professor of Pediatrics and Medical Oncology at the CU School of Medicine.
The practical problem is this: FDA approval of many of these drugs for adult use allows physicians to prescribe the same drugs for pediatric use. Many are pills – orally administered, outpatient treatments that make it difficult to recognize and track possible side-effects even in the short-term, let alone 10, 15 or 60 years later.
"The message I really want to convey is that our way of treating pediatric cancer has changed entirely in some diseases, and in some it's meant huge progress. A number of us have patients who have literally been cured by these new drugs. There are a lot of really cool therapies out there, but the issue is using them safely. With increased survival, we need to cure kids for 60-70 years. The question is how do we best treat these kids, knowing that cancer remains the enemy but you also don't want to induce complications that negatively affect the rest of their lives," Gore says.
"Personally, one of the most important things when choosing how to treat pediatric patients is to know what I don't know – to acknowledge gaps in knowledge. Then as a researcher, we try to fill these gaps so that we can prescribe knowing the balance of risk and reward for these treatments," Porter says.
For now and until these questions are answered, the researchers recommend using molecularly targeted therapies with pediatric patients only in the context of a clinical trial. To Gore, Porter and co-author James DeGregori, PhD, the framework of a clinical trial provides the oversight needed for the rational prescription of these drugs in pediatric patients – along with follow-up that includes more definite monitoring of side-effects than what Gore describes as "random use."
"One of the reasons we wrote this paper is that we don't understand the major risks, or even what the major risks might be," Porter says. "These targeted agents may affect the process of development in ways we can't predict."
Journal reference: Lancet Oncology
Provided by University of Colorado Denver
- Study shows long-term effects of radiation in pediatric cancer patients Aug 21, 2012 | not rated yet | 0
- Lower risk of serious side-effects in trials of new targeted drugs Aug 07, 2012 | not rated yet | 0
- Longer life expectancy, aging population necessitate new strategies for prostate cancer care Dec 04, 2012 | not rated yet | 0
- The current state of lung cancer treatment Dec 11, 2012 | not rated yet | 0
- UCSF Turns to Targeted Treatments to Boost Brain Tumor Survival in Children May 19, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer May 24, 2013 | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer May 24, 2013 | 5 / 5 (1) | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer May 24, 2013 | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer May 24, 2013 | 5 / 5 (2) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer May 24, 2013 | 5 / 5 (4) | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
18 hours ago | 5 / 5 (5) | 5
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
10 hours ago | not rated yet | 1
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
18 hours ago | 5 / 5 (1) | 1
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
May 20, 2013 | 4.8 / 5 (31) | 9 |
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
18 hours ago | not rated yet | 0
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
18 hours ago | not rated yet | 0